WHAT YOU NEED TO KNOW In case you missed it, the Coalition Against Patent Abuse applauded a recent decision by the U.S. House of Representatives’ Committee on Oversight and Reform to subpoena AbbVie, the drug company that makes Humira, as part of its probe into pricing practices by the big drug companies.   “CAPA applauds today’s announcement by the […]

Continue Reading

WHAT YOU NEED TO KNOW In case you missed it, Morning Consult published an op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse, around rising prescription drug prices and the need for reforms that can encourage competition and innovation to drive access and affordability.  In his op-ed, Lane highlights a national survey by the Campaign for […]

Continue Reading

WHAT YOU NEED TO KNOW This week, Axios reported that Humira, a medicine that is prescribed to millions of people around the world, “continues to generate more U.S. revenue than any other drug, due to AbbVie extending U.S. patents and consequently retaining higher U.S. prices.”   WHAT YOU NEED TO KNOW: While Humira is notably one of the […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy.  The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the field, […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, I-MAK released a new report that outlines how AbbVie abuses the U.S. patent system to stave off competition for their critical cancer drug, Imbruvica.  This analysis was also covered by STAT News which showed AbbVie could have its patents on Imbruvica extended through 2036, forcing consumers to spend an additional $41 billion for […]

Continue Reading

WHAT YOU NEED TO KNOW The Coalition Against Patent Abuse (CAPA) along with Niskanen Center, Engine, R Street Institute and other public and private interest groups signed on to a letter sent to the House and Senate Judiciary Committees encouraging them to exercise their oversight authority to investigate procedural changes recently made by the Patent […]

Continue Reading

WHAT YOU NEED TO KNOW Last week, CAPA hosted an online panel on the importance of balancing the needs of innovation, access, and affordability when it comes to drug policy. The panel entitled, “Drug Pricing Debate: Why Drug Innovation, Access & Affordability Matter More Than Ever During COVID-19” welcomed discussion with leading experts in the […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, Barron’s highlighted a study that showed how biosimilars of AbbVie’s Humira have saved Europe a bundle.  Biosimilar versions of the antibody product adalimumab have taken some of Humira’s market in Europe and other countries, dropping AbbVie’s foreign sales of Humira by 27% last year. “Biosimilar versions of the antibody product adalimumab […]

Continue Reading

WHAT YOU NEED TO KNOW This month, The Hill published a timely op-ed by Matthew Lane, executive director of the Coalition Against Patent Abuse.  Lane penned this piece amidst the COVID-19 pandemic to highlight the need to make sure our drug laws are working to encourage innovation and public-private partnerships for the development of needed drugs while […]

Continue Reading

WHAT YOU NEED TO KNOW According to recent reporting from Reuters, lawmakers are watching closely how Gilead will price their drug remdesivir. Remdesivir, which was developed in part through taxpayer funding, has been touted as a potential treatment for COVID-19. “But it has sued Gilead over patents on two of its widely-used HIV drugs that received federal […]

Continue Reading